QurAlis taking three ALS programs toward clinic with $42M series A
A broadened investor syndicate will help QurAlis advance programs targeting disease subpopulations
After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis and genetically-driven frontotemporal dementia.
Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery Fund led the round. Also participating were Droia Ventures, Mitsui Global Investment, Dolby Family Ventures, Amgen Ventures, MP Healthcare Venture Management and Sanford